In the year 2000, the first-ever Antibody-drug Conjugate (ADC) - Mylotarg, was launched by Pfizer and was considered a miracle in cancer treatment. And it appeared like there was no looking back for these antibody-drug conjugates. But it took almost another 11 years for the next ADC to launch in the market - Adectris by Seagen Inc. After twenty years of ongoing clinical trials of ADC research and development, it is now that this field constitutes almost 50 major pharmaceutical companies continuously working to develop a plethora of antibody-drug conjugates targeted to treat a wide range of tumor types.
At present, there are 11 FDA-approved antibody-drug conjugates...
